Related Experiment Video
Updated: Jul 6, 2025

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
Pioglitazone and barriers to effective post-stroke comorbidity management in stroke survivors with diabetes
Hala Azhari1, Jonathan Hewitt1, Alexander Smith1
1From the College of Medicine and Pharmacy (Azhari), Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia, from the School of Cardiovascular and Metabolic Health (Azhari, Quinn, Dawson), University of Glasgow, Glasgow, from the School of Geriatric Medicine Centre (Hewitt, O'Neill), Cardiff University, and from the Clinical Research and Innovation Centre (Smith), Aneurin Bevan University Health Board, Newport, United Kingdom.
Objectives:
To explore the barriers preventing pioglitazone use in stroke survivors and primary and secondary stroke care services.
Methods:
A qualitative grounded theory approached design was used to assess post-stroke diabetes treatments and to assess clinical applicability of pioglitazone as a preventive treatment to minimize its side effects (SEs) associated. Three focus groups were established with 48 participants from Scotland and Wales health board centers during January 2019 to July 2022.
Results:
A qualitative grounded theory approached design was used to assess post-stroke diabetes treatments and to assess clinical applicability of pioglitazone as a preventive treatment to minimize its SEs associated. Three focus groups were established with 48 participants from Scotland and Wales health board centers during January 2019 to July 2022.
Conclusion:
These strategies might allow greater treatment adherence by stroke survivors and increased confidence of the health care professionals in their practice. The findings suggest that further research will be needed to facilitate wider usage of pioglitazone in treating people with stroke and health education is necessitate when using diabetes drugs post-stroke.
More Related Videos
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides

